Patients with moderate to severe atopic dermatitis experienced a 71% decrease in Eczema Area and Severity Index scores from ...

Now, a new evidence review has identified the most effective treatments for people who suffer from chronic hives.

With few real-life studies that have specifically focused on how atopic dermatitis (AD) affects patients living with the ...

Dupilumab in patients with diffuse type 2 CRSwNP had beneficial changes in nasal passage microbiota but did not alter gastrointestinal microbiota.

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

A new international study led by researchers at McMaster University has identified the most effective and safest treatments ...

Patients with asthma and allergic bronchopulmonary aspergillosis experienced improvements with dupilumab, according to data ...

Treatment with dupilumab is associated with weight gain in about two thirds of adults with atopic dermatitis over 3-6 months, ...

Introducing lebrikizumab for severe atopic dermatitis in Italy may result in cost savings for the national health system, a ...

Patients with AD treated with dupilumab have a lower risk of various infections than those treated with methotrexate or cyclosporine.

Since its release in 2017, dupilumab (a fully humanized monoclonal antibody that blocks IL-4 and IL-13) has transformed the therapeutic landscape for managing atopic dermatitis (AD) and other ...

PARIS and TARRYTOWN, N.Y., Oct. 16, 2018 /PRNewswire/ -- Two pivotal Phase 3 placebo-controlled trials evaluating Dupixent ® (dupilumab) in adults with inadequately-controlled chronic ...